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Background: WNV epidemics occur worldwide, new WNV isolates were isolated in southern-east 
Europe belonging to WNV lineage 2. A first international proficiency study on WNV indicted that some 
laboratories were not able to detect WNV lineage 2 virus genome by their PCR diagnostic assays. 
Therefore an actual External Quality Assessment with both virus lineages was performed to monitor 
the improvements in molecular diagnostics. 
 
Objectives: To asses the proficiency of laboratories to detect West Nile virus with molecular 
diagnostic tests. 
Study design: A test panel of different WNV isolates and virus dilutions was given to 26 laboratories 
to test the samples with their routine diagnostic methods. 
Results: Twenty-one participating laboratories provided 28 data set results. WNV lineage 1 was 
detected with high overall efficiency of 92% (67.9–100%) but two different WNV lineage 2 strains were 
detected at lower rates (mean = 73%, 67.9–75%) by the different PCR assays. 93% of the laboratories 
were able to detect a WNV lineage 1 with a concentration of 1.2 × 10
4
 copies/ml but the detection rate 
was decreased to 68% for 1.2 × 10
3
 copies/ml. One laboratory generated false-positive result from the 
non-virus control samples and 29% of the datasets showed false-positive results for non-WNV 
flavivirus samples. 
 
Conclusions: The WNV EQA showed an improved proficiency of laboratories as compared to the first 
EQA. However, the data suggest that problems in the detection of both lineages were still present 
since the first proficiency test was performed in 2006. Further proceedings versus the detection of both 
lineages are needed particularly for in-house assays. 
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West Nile virus (WNV) belongs to the genus Flavivirus in the family Flaviviridae.
1
 Phylogenetic studies 
based on amino acid substitutions or deletions in the envelope proteins show that WNV can be 
separated into two major lineages. WNV lineage 1 is responsible for epidemics in the western 
hemisphere, and it is assumed that these viruses are particularly pathogenic for vertebrates such as 
birds, humans and horses.
2
 WNV lineage 2 is endemic in Southern Africa and Madagascar
3
 and it was 
postulated to be non-pathogenic in horses and is maintained in endozootic cycles.
 [4] and [5]
 New studies 
show that variants of WNV lineage 2 can be neuroinvasive in mice or can cause severe symptoms in 
horses or humans.
 [3], [6] and [7]
 Recently WNV genotype lineage 2 became more prevalent in Europe and 
new strains were isolated in Central Europe.
8
 In summer 2010 WNV epidemics occurred in Southeast 
Europe (Greece, Turkey, Russia, and Romania). The epidemic in Greece might be causative 
associated with WNV lineage 2 viruses.
9
 In 2006 a first proficiency study was performed regarding the 
molecular detection of WNV. Laboratories generally showed a good performance in detecting WNV 
lineage 1 but 43% of laboratories were unable to detect WNV lineage 2.
10
 The recent external quality 
assessment (EQA) should be seen as a confirmation of improved WNV molecular diagnosis versus 
detection of both WNV lineages and the specificity of the WNV molecular diagnostic. 
 
2. Objectives 
The aim of this EQA was to evaluate the proficiency of laboratories to detect West Nile virus with 
molecular diagnostic tests. 
 
3. Study design 
The WNV EQA Programme test panel consisted of nine coded samples containing WNV viruses of 
lineages 1 and 2 plus 3 control samples. Lineage 1 WNV was represented by WNV NY99 whereas for 
WNV lineage 2 WNV Uganda B956 (kindly provided by G. Wengler), and WNV (goshawk-Hungary/04 
kindly provided by Emöke Ferenzi) were used. Two mixed samples consisting of different other 
flaviviruses like Japanese encephalitis virus, Dengue virus 1, 2, and 4 or rather Dengue 3, Yellow 
fever virus 17D, and Tick borne encephalitis virus were added to the panel to analyse the specificity of 
the PCR assays. All virus samples were inactivated by heat (56 °C, 1 h) and gamma irradiated before 
diluted in virus transport medium (VTM; 10% fetal calf serum in Dulbecco's Modified Eagle's Medium) 
to concentrations of 1.2 × 10
7
 to 1.2 × 10
3
 copies/ml. Testing was performed on all samples in their 
final form which showed that they performed to expectation. The lyophilised samples were shipped to 
the participants in July 2010. 
26 laboratories from 12 European and non-European countries received the EQA samples from which 
21 returned one or two data stets of results obtained by different PCR assays. The laboratories were 
asked to test the panel samples by their routine molecular diagnostic WNV test and to provide a 
dataset for qualitative and/or quantitative results. The data were analysed in order to asses the 




Twenty-one participating laboratories (81%) returned 28 datasheets of which 10 (36%) were 
qualitative and quantitative. Eight of these 28 datasets (29%) stated conventional in-house 
polymerase chain reaction (PCR), 7 (25%) commercial real time assays and 13 (46%) laboratories 
used in-house real time assays. 
Aim of this EQA was to assess the proficiency of laboratories to detect WNV lineage 1 in 
concentrations between 1.2 × 10
7
 and 1.2 × 10
4
 copies/ml WNV NY 99 virus (#1–5) and WNV 
genotype lineage 2 isolate WNV goshawk-Hungary/04 (# and WNV Uganda B956 in concentrations of 
1.1 × 10
5
 to 7.3 × 10
6
 copies/ml and one negative control respectively by all laboratories (Table 1; #7–
9). 
  
When applying these criteria, 75% of the laboratories passed the minimum requirements for 
successful participation. Considering that the sensitivity for a diagnostic PCR should be roughly 
10
3
 copies/ml and that WNV lineage 2 is only detected by 68–75% of the laboratories a significant 
improvement is recommended for these laboratories (Table 1). Regarding the technology type and 
their sensitivity, commercial real time methods detected all WNV samples accurately. In-house real 
time PCR methods detected most of the dilution series correctly. Using conventional PCR for WNV 
detection false negative results of the different concentrated WNV solutions were given for three 
samples. 
Looking at the details of the proficiency to detect WNV lineage 2, all commercial assays were able to 
detect both isolates (#7–9). 54% of the laboratories providing results based on in-house real-time PCR 
were able to detect the samples of WNV lineage 2 and 46% were able to detect the second strain 
Uganda B956. Using conventional PCR 88% of the datasheets described the detection of WNV 
goshawk and 75% were able to detect WNV Uganda B956. 
Two samples of the EQA panel contained heterologous non-WNV flaviviruses to test the specificity of 
the WNV diagnostics. Four out of 28 datasets generated false-positive WNV results for each non-WNV 
flavivirus sample (#10, #11). These false-positive results can be correlated with PCR systems 
targeting the following genes: 3′UTR, 5′UTR, envelope protein, NS5 and target genes not otherwise 
reported (Table 2). 
The VTM only negative sample was reported false positive by one participant (4%) using a 
conventional in-house PCR targeting the NS5 region pointing to a basic contamination problem in the 
lab setting (Table 2). 
 
5. Discussion 
Since WNV linage 2 was recently introduced into Europe the detection of both lineages by PCR is 
mandatory for a diagnostic laboratory.
8
 The unsatisfying results of the first external quality assessment 
study for quality of PCR diagnostic of WNV genome clearly show the gaps and needs to improve the 
assay perfomance.
10
 In this study 16 out of 30 laboratories failed to detect linage 2. In contrast to the 
WNV outbreak 1996–1997 in Romania caused by linage 1 the WNV outbreak in Northern Greece in 
2010 was also related to linage 2 and was accompanied by some death in older people.
11
 The 
presented quality assessment study still demonstrates that one third of the laboratories must improve 
their PCR assays regarding detection of linage 2 to allow the detection of all relevant WNV strains at 
risk for future outbreaks. 
Besides the specificity of WNV diagnostics the EQA monitors the sensitivity of PCR methods. A WNV 
concentration of 1.2 × 10
4
 copies/ml was detected by 93% whereas 1.2 × 10
3
 copies/ml were detected 
only by 68% of the laboratories. This is a clear loss of sensitivity, which affected only in-house PCR 
systems. Results of WNV screening in blood donors showed that the viral load of WNV in plasma 
samples was between 1.1 × 10
2
 to 7.6 × 10
3
 copies/ml and 5.7 × 10
1
 to 8.4 × 10
2
 copies RNA/ml 
respectively.
 [12] and [13]
 In fact, plasma is often used for WNV diagnostics, precaution is necessary 
concerning the sensitivity of WNV PCR method. 
Incorrect results were obtained with non-WNV Flaviviruses and with the true negative control, which 
was already stated by the EQA in 2006. 
In conclusion this EQA provided interesting results regarding the proficiency of laboratories involved in 
molecular detection of WNV. Laboratories must improve their performances in the sensitive detection 
and correct amplification of WNV genotype lineage 2 so that inaccuracies in diagnosis can be avoided. 
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Tables and Figures 
 
 
Table 1. Number of correct qualitative results per panel member and technology type. 
  
Table 2. Analysis of the qualitative data by assay target gene, out of the 28 datasets 19 (67.9%) 
contained information on the target gene. 
 
 
 
